AR126813A1 - Nueva nanopartícula lipídica termostable y métodos de uso de la misma - Google Patents

Nueva nanopartícula lipídica termostable y métodos de uso de la misma

Info

Publication number
AR126813A1
AR126813A1 ARP220102218A ARP220102218A AR126813A1 AR 126813 A1 AR126813 A1 AR 126813A1 AR P220102218 A ARP220102218 A AR P220102218A AR P220102218 A ARP220102218 A AR P220102218A AR 126813 A1 AR126813 A1 AR 126813A1
Authority
AR
Argentina
Prior art keywords
independently
chr
varies
hpv
formula
Prior art date
Application number
ARP220102218A
Other languages
English (en)
Inventor
Andrew Bett
Izzat Raheem
Jason W Skudlarek
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR126813A1 publication Critical patent/AR126813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Abstract

La presente divulgación proporciona, entre otras cosas, una composición adyuvante de nanopartículas lipídicas. La presente divulgación proporciona composiciones farmacéuticas que incluyen un adyuvante estable de nanopartículas lipídicas y partículas similivíricas (las PSV) de papilomavirus humano (PVH) de al menos un tipo de papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos de PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82. Reivindicación 1: Un PEG-lípido que tiene la estructura expuesta en la fórmula (1) en donde: cada m varía independientemente de 5 - 20; n varía de 20 - 60; p es 0, 1 o 2; cada X es independientemente CH₂, CHR, CR₂ o C=O; cada Y es independientemente CH₂, CHR, CR₂ o NH; cada Z está independientemente ausente o es CH₂ o NH; y cada R es independientemente alquilo C₁-C₆, arilo C₆-C₁₀, heteroalquilo C₁-C₆ o heteroarilo C₆-C₁₀. Reivindicación 2: Una nanopartícula lipídica que comprende: (a) un PEG-lípido que tiene la estructura expuesta en la fórmula (1) en donde: cada m varía independientemente de 5 - 20; n varía de 20 - 60; p es 0, 1 o 2; cada X es independientemente CH₂, CHR, CR₂ o C=O; cada Y es independientemente CH₂, CHR, CR₂ o NH; cada Z está independientemente ausente, CH₂ o NH; y cada R es independientemente alquilo C₁-C₆, arilo C₆-C₁₀, heteroalquilo C₁-C₆ o heteroarilo C₆-C₁₀; y (b) un fosfolípido. Reivindicación 17: Una composición farmacéutica que comprende: partículas similivíricas (las PSV) de al menos un tipo de papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos de PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73 y 82, un PEG-lípido que tiene la estructura expuesta en la fórmula (1) en donde: cada m varía independientemente de 5 - 20; n varía de 20 - 60; p es 0, 1 o 2; cada X es independientemente CH₂, CHR, CR₂ o C=O; cada Y es independientemente CH₂, CHR, CR₂ o NH; cada Z está independientemente ausente, CH₂ o NH; y cada R es independientemente alquilo C₁-C₆, arilo C₆-C₁₀, heteroalquilo C₁-C₆ o heteroarilo C₆-C₁₀; y un transportador farmacéuticamente aceptable. Reivindicación 18: Una composición farmacéutica que comprende: partículas similivíricas (las PSV) de al menos un tipo de papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos de PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73 y 82, un fosfolípido que tiene la estructura expuesta en la fórmula (3); y un transportador farmacéuticamente aceptable. Reivindicación 19: Una composición farmacéutica que comprende: (a) partículas similivíricas (las PSV) de al menos un tipo de papilomavirus humano (PVH) seleccionado del grupo que consiste en los tipos de PVH: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73 y 82, y (b) una nanopartícula lipídica (NPL); en donde la NPL comprende: (i) un PEG-lípido que tiene la estructura expuesta en la fórmula (1) en donde: cada m varía independientemente de 5 - 20; n varía de 20 - 60; p es 0, 1 o 2; cada X es independientemente CH₂, CHR, CR₂ o C=O; cada Y es independientemente CH₂, CHR, CR₂ o NH; cada Z está independientemente ausente, CH₂ o NH; y cada R es independientemente alquilo C₁-C₆, arilo C₆-C₁₀, heteroalquilo C₁-C₆ o heteroarilo C₆-C₁₀; y (ii) un fosfolípido que tiene la estructura expuesta en la fórmula (3).
ARP220102218A 2021-08-19 2022-08-17 Nueva nanopartícula lipídica termostable y métodos de uso de la misma AR126813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163235014P 2021-08-19 2021-08-19

Publications (1)

Publication Number Publication Date
AR126813A1 true AR126813A1 (es) 2023-11-15

Family

ID=83193481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102218A AR126813A1 (es) 2021-08-19 2022-08-17 Nueva nanopartícula lipídica termostable y métodos de uso de la misma

Country Status (7)

Country Link
US (1) US20230118665A1 (es)
KR (1) KR20240046247A (es)
AR (1) AR126813A1 (es)
AU (1) AU2022331279A1 (es)
CA (1) CA3229064A1 (es)
TW (1) TW202315602A (es)
WO (1) WO2023023152A1 (es)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ES2264563T3 (es) 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
CA2259179C (en) 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
DE60333035D1 (de) 2002-12-23 2010-07-29 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
AU2006239422A1 (en) 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20100076055A1 (en) 2008-04-16 2010-03-25 Abbott Laboratories Cationic Lipids and Uses Thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
US20100055168A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
WO2010030730A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010030739A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
JPWO2010146740A1 (ja) 2009-06-17 2012-11-29 シャープ株式会社 表示駆動回路、表示装置及び表示駆動方法
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
SG181904A1 (en) 2009-12-23 2012-07-30 Novartis Ag Lipids, lipid compositions, and methods of using them
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
CN103167866B (zh) 2010-09-20 2015-09-23 瑟纳治疗公司 用于寡核苷酸递送的新型低分子量阳离子脂质
US20160317444A1 (en) * 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Liposomal Formulations for Allosteric AKT Inhibitors
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2021219652A1 (en) * 2020-02-14 2022-08-18 Merck Sharp & Dohme Llc HPV vaccine

Also Published As

Publication number Publication date
AU2022331279A1 (en) 2024-02-15
US20230118665A1 (en) 2023-04-20
KR20240046247A (ko) 2024-04-08
TW202315602A (zh) 2023-04-16
CA3229064A1 (en) 2023-02-23
WO2023023152A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
AR019114A1 (es) Nuevas microesferas a base de poli(metiliden malonato), su procedimiento de preparacion y composiciones farmaceuticas que las contienen
CO5560559A2 (es) Formulacion de suspension oral estabilizada
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
BRPI0712142A8 (pt) Formulações farmacêuticas para a liberação prolongada de princípio(s) ativo(s), bem como suas aplicações, especialmente aplicações terapêuticas
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
DE69940769D1 (de) Orale flüssige zusammensetzungen
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
RU2005132309A (ru) Мицелярный препарат, содержащий малорастворимый в воде противораковый агент и новый блоксополимер
DE602005025082D1 (de) Nicht-lamellare zubereitungen von dioleoyl-phosphatidyl ethanolamin und polysorbat80
Ke et al. Bifunctional fusion membrane‐based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells
AR029499A1 (es) Derivados de pirrolidina, farmaceuticamente activos, aplicables en el tratamiento y/o prevencion de partos y/o nacimientos prematuros y/o dismenorrea, uso de dichos derivados en la preparacion de composiciones farmaceuticas para dichos tratamientos y proceso de preparacion de los derivados mencionad
AR126813A1 (es) Nueva nanopartícula lipídica termostable y métodos de uso de la misma
MX2023005696A (es) Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas.
BR112022003046A2 (pt) Conjugados de il-15 e usos dos mesmos
JPS61500729A (ja) 抗腫瘍医薬組成物及びその製造法
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NO20060506L (no) Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter
FR2623504B1 (fr) Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
RU94038254A (ru) Циклические аминопроизводные, способ их получения, фармацевтические композиции и способ их получения
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
BR112023008972A2 (pt) Copolímeros de poliglicin-poli(alquilenimina) funcionalizados, sua produção e uso para a preparação de formulações de substâncias ativas e substâncias de efeito
RU2009101495A (ru) Фармацевтическая композиция для введения инъекций
DE60326731D1 (de) Arzneizubereitung und deren anwendung zur behandlu